Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...
The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...
A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...
Roche secures Zealand obesity drug candidate for up to $5.3 billion Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion ...
5d
Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...
The Delhi High Court on Monday dismissed an interim injunction application filed by Swiss pharmaceutical giant F Hoffmann-La ...
"Roche has filed an appeal against the Hon. Delhi High Court order and the matter is subjudice in the appeal court," Roche ...
For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback